顾云燕，博士生导师，哈尔滨医科大学生物信息科学与技术学院副院长，系统生物学教研室主任，黑龙江省高层次人才，哈尔医科大学星联人才。
团队网站：http://www.medsysbio.org/GuLab/
个人邮箱：guyunyan@ems.hrbmu.edu.cn
研究方向：复杂疾病生物信息学
个人简介：
长期致力于复杂疾病的生物信息学创新研究，基于多组学整合分析与人工智能算法，深入解析器官纤维化及肿瘤微环境的跨尺度动态网络机制，系统性筛选与验证潜在药物靶点及疗效预测标志物，助力精准治疗策略的开发。在《Science Advances》等高水平期刊上发表研究论文70余篇，其中以第一作者或通讯作者身份发表45篇。主持11项科研项目（包括4项国家自然科学基金），作为课题骨干参与2项国家重点研发项目。研究成果荣获黑龙江省科学技术奖三等奖、黑龙江省医药卫生科学技术二等奖等多项荣誉。中国抗癌协会肿瘤标志专业委员会肿瘤测序及大数据分析协作组委员，黑龙江省体质康复学会副会长，黑龙江省生物信息学会理事，黑龙江省女医生协会乳腺肿瘤专委会委员。参编教材3部，获得发明专利4项，并荣获哈尔滨医科大学青年五四奖章。
学习和工作经历：
2003.9-2007.7哈尔滨医科大学基础医学学士
2007.9-2011.6哈尔滨医科大学生物物理学（生物信息方向）博士
2011.7-2012.8哈尔滨医科大学计算系统生物学讲师
2012.9-2017.8哈尔滨医科大学计算系统生物学副教授
2017.9-至今哈尔滨医科大学计算系统生物学教授
主持科研项目：
1. 科技部国家重点研发计划子课题，基于多尺度跨时空异构数据构建肿瘤乏氧数字孪生系统：鼻咽癌乏氧数字孪生系统临床示范应用（2023YFF1204600），2023/11-2026/12，44.9万，在研，课题骨干。
2. 国家自然科学基金面上基金，基于多组学数据预测免疫检查点抑制剂相关心肌炎风险和疾病机制解析（32470702），2025/01-2028/12，50万，在研，主持。
3. 国家自然科学基金面上基金，基于多组学数据解析合成致活效应在非小细胞肺癌对免疫检查点抑制剂耐药中的作用与机制（32270710），2023/01-2026/12，54万，在研，主持。
4. 黑龙江省省属科研院所科研业务费项目,免疫治疗相关不良反应风险预测及机制分析（CZKYF2024-1-A010），2024/01-2025/12，50万，在研，主持。
5. 黑龙江省自然科学基金优秀青年项目:基于癌基因组遗传互作识别PARP抑制剂药效标志并解析耐药机制(YQ2021H005)，2021/7-2024/7，10万，在研，主持。
6. 国家自然科学基金面上基金：基于基因间遗传互作解析癌症靶向药物耐药机制（61673143），2017/01-2020/12，61万，结题，主持。
7. 国家自然科学基金青年基金：基于蛋白质互作网络识别癌相关共扰动模块并解析其功能协同机制（81201822），2013/01-2015/12，23万，结题，主持。
8. 黑龙江省教育厅科学技术研究项目：基于单样本miRNA表达模式识别乳腺癌生存标志物（12541330），2014/01-2016/12，2.5万，结题，主持。
9. 中国博士后科学基金：胶质母细胞瘤相关功能模块共扰动机制研究（2012M510988），2012/01-2014/12，5万，结题，主持。
10. 黑龙江省政府博士后资助基金：基于癌基因组高通量数据识别癌症治疗靶点
（LRB2011289），2012/01-2014/12，2万，结题，主持。
11. 黑龙江省博士后科研启动金：基于癌基因组高通量数据研究癌细胞耐药机制
（LBH-Q16166），2017/01-2019/12，7万，结题，主持。
奖项：
1. 2020年6月，黑龙江省医药卫生科学技术二等奖，癌症协同扰动模块分析方法研究及其预后标志识别，顾云燕，戚丽霜，赵章翔，赵文媛，常志强
2. 2017年10月,黑龙江省科学技术奖三等奖，非可控性炎症向癌症转化的分子机制研究，郭政，顾云燕，戚丽霜，赵文媛，梁海海。
3. 2017年3月，哈尔滨医科大学青年科技人才奖。
4. 2016年11月,哈尔滨市科学技术进步三等奖，融合组学挖掘非可控性炎症向癌症转化的分子机制，郭政，顾云燕，戚丽霜，赵文媛，梁海海。
5. 2016年10月，哈尔滨医科大学“三育人”工作先进个人。
6.《启智医“声”——新医学智能教育用具领航者》，第七届黑龙江“互联网+”大学生创新创业大赛，2020.8，银奖，指导教师。
7.《启智医“声”——新医学智能教育用具领航者》，2021年iCAN全国大学生创新创业大赛黑龙江赛区，三等奖，指导教师
8. 基于癌基因组识别靶向药物耐药标志和敏感标志，2019届本科优秀毕业论文，指导教师。
9. 全国大学生统计建模大赛，优秀奖，证书号：2019IVAD001，2019.11，指导教师。
专利：
1. 类型：发明；名称：基于影像组学定性算法构建癌症临床指标评估系统；批准时间：2021.1.12；专利号：ZL202110038828.6；发明人：戚丽霜，刘宜鑫，王可铮，顾云燕，赵文媛，常志强，杨丽萍，李昕，李梦玥，亓海涛。
2. 类型：发明；名称：一种中晚期结直肠癌治疗方案决策算法；批准时间：2024.9.3；专利号：ZL 2022 1 0001215.X；发明人：赵文媛，李可如，王永通，常志强，顾云燕，戚丽霜，刘志新。
3. 类型：发明；名称：一种基于遗传互作特征的抗肿瘤药物药效预测方法及系统；申请时间：2024.4.22；申请号：2024104793449；发明人：顾云燕，刘明月，陈博，刘凯东，梁海海。
4. 类型：发明；名称：三阴性乳腺癌预后标志、预后评估方法和标志筛选方法；申请时间：2024.4.22；申请号：2024104793491；发明人：顾云燕，徐欢欢，梁海海，戚丽霜，赵文媛，李昕。
发表文章（部分）:
1. Kaidong Liu#, Yanrui Cui#, Huiming Han#, Erliang Guo, Xingyang Shi, Kai Xiong, Nan Zhang, Songmei Zhai, Shaocong Sang, Mingyue Liu, Bo Chen,Yunyan Gu*. Fibroblast atlas: shared and specific cell types across tissues. Science Advances. 2025. Accepted.
2. Tongzhu Jin#，Huiying Gao#, Yuquan Wang#, Zhiwei Ning1#, Yan Wang, Yi Chen, XiaomuTian, Qiudi Liu, Zhihui Niu, Jiayu Guo, Jian Sun, Ruoxuan Yang, Tianyu Li, Yuhong Zhou, Wenxin He*, Yanjie Lu*,Yunyan Gu*, Haihai Liang*. SRSF7 promotes pulmonary fibrosis through regulation of PKM alternative splicing in lung fibroblasts. Acta Pharmaceutica Sinica B. 2025. Accepted.
3. Qi Dong#, Yingying Guo#, Chen Lv#, Lingxue Ren, Bo Chen, Yan Wang, Yang Liu, Mingyue Liu, Kaidong Liu, Nan Zhang, Linzhu Wang, Shaocong Sang, Xin Lia, Yang Hui*, Haihai Liang*,Yunyan Gu*.Unveiling a novel cancer hallmark by evaluation of neural infiltration in cancer. Briefings in Bioinformatics.2025 Mar 4;26(2):bbaf082. doi: 10.1093/bib/bbaf082.
4. Wenyue Li#, Linzhu Wang#, Wen Tian#, Weihang Ji, Danyang Bing, Yan Wang, Bingqian Xu, Jiayue Feng, Peng Zhang, Haihai Liang,Yunyan Gu*, Baofeng Yang*. SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression. JCI Insight. 2024 Dec 20;9(24):e185269. doi: 10.1172/jci.insight.185269.
5. Zhangxiang Zhao#, Yuquan Wang#, Zixin Jin, Huiming Han, Bo Chen, Mingyue Liu, Kaidong Liu, Shuping Zhuang, Haihai Liang*,Yunyan Gu*. Alternative splicing of immune-related genes identifies breast cancer subtypes with differential immune cell infiltration. Genes & Disease. 2024 Jun 14;12(2):101349. doi: 10.1016/j.gendis.2024.101349
6. Kaidong Liu#,Huiming Han#,Kai Xiong#,Songmei Zhai,Xiuqi Yang,Xinmiao Yu,Bo Chen,Mingyue Liu,Qi Dong,Hongxue Meng*,Yunyan Gu*. Single-cell landscape of intratumoral heterogeneity and tumor microenvironment remolding in pre-nodal metastases of breast cancer.Journal of Translational Medicine. 2024 Aug 29;22(1):804. doi: 10.1186/s12967-024-05625-6.
7. Mingyue Liu#,Zhangxiang Zhao#,Chengyu Wang#,Shaocong Sang,Yanrui Cui,Chen Lv,Xiuqi Yang,Nan Zhang,Kai Xiong,Bo Chen,Qi Dong,Kaidong Liu,Yunyan Gu*. Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells. Cancer Letters. 2024 Jul 10:594:216991.doi: 10.1016/j.canlet.2024.216991.
8. Yuquan Wang#,Erliang Guo#,Min Zou#,Chen Lv,Yanrui Cui,Songmei Zhai,Shaocong Sang,Kai Xiong,Xiuqi Yang,Shuping Zhuang,Yunyan Gu*,Haihai Liang*. Unraveling immune heterogeneity across pan-cancer and deep insights in lung adenocarcinoma based on alternative splicing. Journal of Leukocyte Biology. 2024 May 17:qiae104. doi: 10.1093/jleuko/qiae104.
9. Tingting Chen#,Jiayu Guo#,Liqiang Ai#,Yuquan Wang,Yan Wang,Bo Chen,Mingyue Liu,Shuping Zhuang,Kaidong Liu,Zhangxiang Zhao,Haihai Liang*,Yunyan Gu*.Up-regulated SPP1 increases the risk from IPF to lung cancer via activating the pro-tumor macrophages.Computational and Structural Biotechnology Journal. 2023 Nov 14:21:5751-5764.
10. Qi Dong#,Tong Yu#,Bo Chen,Mingyue Liu,Xiang Sun,Huiying Cao,Kaidong Liu,Huanhuan Xu,Yuquan Wang,Shuping Zhuang,Zixin Jin,Haihai Liang,Yang Hui*,Yunyan Gu*. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway.JCI Insight. 2023 Nov 8;8(21):e165268.
11. Mingyue Liu#,Qi Dong#,Bo Chen,Kaidong Liu,Zhangxiang Zhao,Yuquan Wang,Shuping Zhuang,Huiming Han,Xingyang Shi,Zixin Jin,Yang Hui*,Yunyan Gu*.Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells, British Journal of Cancer, 2023 Oct;129(8):1339-1349.
12. Sainan Zhang#,Mengyue Li#,Yilong Tan,Juxuan Zhang,Yixin Liu,Wenbin Jiang,Xin Li,Haitao Qi,Lefan Tang,Ran Ji,Wenyuan Zhao,Yunyan Gu*,Lishuang Qi*. Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.Journal of Molecular Medicine. 2022 Dec;100(12):1755-1769.
13. Bo Chen#, Pengfei Li#, Mingyue Liu#, Kaidong Liu, Min Zou, Yiding Geng, Shuping Zhuang, Huanhuan Xu, Linzhu Wang, Tingting Chen, Yawei Li, Zhangxiang Zhao, Lishuang Qi*,Yunyan Gu*.A genetic map of the chromatin regulators to drug response in cancer cells. Journal of Translational Medicine. 2022 Sep 30;20(1):438.
14. Tingting Chen#,Tong Yu#,Shuping Zhuang,Yiding Geng,Junwen Xue,Jiayi Wang,Liqiang Ai,Bo Chen,Zhangxiang Zhao,Yawei Li,Jinghao Wang,Haihai Liang,Yan Xu*,Yunyan Gu*. Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade. British Journal of Cancer. 2022 Sep;127(5):916-926.
15. Kaidong Liu#, Yiding Geng#, Linzhu Wang#, Huanhuan Xu, Min Zou, Yawei Li, Zhangxiang Zhao, Tingting Chen, Fengyan Xu, Liang Sun, Shuliang Wu*,Yunyan Gu*. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Molecular Oncology. 2022 Aug;16(16):3034-3051.
16. Hailong Zheng#, Jiajing Xie#, Kai Song, Jing Yang, Huiting Xiao, Jiashuai Zhang, Keru Li, Rongqiang Yuan, Yuting Zhao,Yunyan Gu*and Wenyuan Zhao*. StemSC: a cross-dataset human stemness index for single-cell samples. Stem Cell Research & Therapy. 2022 Mar 21;(2022)13:115.
17. Shuping Zhuang#, Tingting Chen#, Yawei Li#, Yuquan Wang, Liqiang Ai, Yiding Geng, Min Zou, Kaidong Liu, Huanhuan Xu, Linzhu Wang, Zhangxiang Zhao,Zhiqiang Chang*,Yunyan Gu*. Atranscriptional signature detects homologous recombination deficiencyin pancreatic cancerat the individual level. Molecular Therapy-Nucleic Acids. 2021 Oct 20;26:1014-1026.
18. Yawei Li#, Zhangxiang Zhao#, Liqiang Ai, Yuquan Wang, Kaidong Liu, Bo Chen, Tingting Chen, Shuping Zhuang, Huanhuan Xu, Min Zou,Yunyan Gu*,Xia Li*. Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer. iScience. 2021 Sep 17;24(10):103135.
19. Qi Dong#,Mingyue Liu#,Bo Chen#,Zhangxiang Zhao,Tingting Chen,Chengyu Wang,Shuping Zhuang,Yawei Li,Yuquan Wang,Liqiang Ai,Yaoyao Liu1,Haihai Liang,Lishuang Qi,Yunyan Gu*. Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome. Comput Struct Biotechnol J. 2021 Aug 10;19:4435-4446.
20. Zhangxiang Zhao#,YingYing Guo#,Yaoyao Liu#,Lichun Sun,Bo Chen,Chengyu Wang,Tingting Chen,Yuquan Wang,Yawei Li,Qi Dong,Liqiang Ai,Ran Wang,Yunyan Gu*,Xia Li*. Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer. Oncogene. 2021 Jul;40(27):4604-4614.
21. Tingting Chen#,Yingying Guo#,Jiayi Wang#,Liqiang Ai,Lu Ma,Wenxin He,Zhixin Li,Xiaojiang Yu,Jinrui Li,Xingxing Fan,Yunyan Gu*,Haihai Liang*. LncRNA CTD-2528L19.6 prevents the progression of IPF by alleviating fibroblast activation.Cell Death & Disease. 2021 Jun 10;12(6):600.
22. Haihai Liang#, Mengxue Yu#, Rui Yang#, Lu Zhang , Lijia Zhang, Di Zhu, Hongwei Luo, Yaozhen Hong, Tong Yu, Jian Sun, Hongli Shan*,Yunyan Gu*. A PTAL-miR-101-FN1 axis promotes EMT and invasion-metastasis in serous ovarian cancer. Molecular Therapy–Oncolytics. 2019 Dec 11;16,53-62.
23. Chengyu Wang#, Fan Yang#, Tingting Chen, Qi Dong, Zhangxiang Zhao, Yaoyao Liu, Bo Chen, Haihai Liang, Huike Yang*,Yunyan Gu*. RHPCG: a database of the Regulation of the Hippo Pathway in Cancer Genome. Database (Oxford). 2019 Jan 1;2019:baz135.
24. Yue Han#, Chengyu Wang#, Qi Dong#, Tingting Chen, Fan Yang, Yaoyao Liu, Bo Chen, Zhangxiang Zhao, Lishuang Qi, Wenyuan Zhao, Haihai Liang, Zheng Guo*,Yunyan Gu*. ­­­Genetic interactions-based biomarkers identification for drug resistance and sensitivity in cancer cells. Molecular Therapy-Nucleic Acids. 2019 Sep 6;17:688-700.
25. Ruiping Wang#, Yue Han#, Zhangxiang Zhao, Fan Yang, Ya Han, Tingting Chen, Xianlong Wang, Lishuang Qi, Wenyuan Zhao, Zheng Guo*,Yunyan Gu*. Link synthetic lethality to drug sensitivity of cancer cells. Briefings in Bioinformatics. 2019 Jul 19;20(4):1295-1307.
26. Yunyan Gu#, Ruiping Wang#, Yue Han, Wenbin Zhou, Zhangxiang Zhao, Tingting Chen, Yuanyuan Zhang, Fuduan Peng, Haihai Liang, Lishuang Qi, Wenyuan Zhao, Da Yang*, Zheng Guo*.A landscape of synthetic viable interactions in cancer. Briefings in Bioinformatics. 2018 Jul 20;19(4):644-655.
27. Wenbin Zhou#, Zhangxiang Zhao#, Ruiping Wang, Yue Han, Chengyu Wang, Fan Yang, Ya Han, Haihai Liang, Lishuang Qi, Chenguang Wang, Zheng Guo*,Yunyan Gu*. Identification of driver copy number alterations in diverse cancer types and application in drug repositioning. Molecular oncology. 2017 Oct;11(10):1459-1474.(Cover Image)
28. Fuduan Peng#, Ruiping Wang#, Yuanyuan Zhang#, Zhangxiang Zhao, Wenbin Zhou, Zhiqiang Chang, Haihai Liang, Wenyuan Zhao, Lishuang Qi, Zheng Guo*,Yunyan Gu*. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Molecular Cancer. 2017 Jun 6;16(1):98.
29. Zhangxiang Zhao#, Wenbin Zhou#, Yue Han, Fuduan Peng, Ruiping Wang, Ruihan Yu, Chengyu Wang, Haihai Liang, Zheng Guo*,Yunyan Gu*. EMT-Regulome: a database for EMT-related regulatory interactions, motifs and network. Cell Death & Disease. 2017 Jun 15;8(6):e2872.
*通讯作者，#并列第一作者
